Cargando…
Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission
BACKGROUND: Achieving lasting remission for at least 2 years is a good indicator for favourable prognosis long term after Diffuse large B-cell lymphoma (DLBCL). The aim of this study was to provide real-world probabilities, useful in risk communication and clinical decision-making, of the chance for...
Autores principales: | Ekberg, Sara, Crowther, Michael, Harrysson, Sara, Jerkeman, Mats, E. Smedby, Karin, Eloranta, Sandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596493/ https://www.ncbi.nlm.nih.gov/pubmed/35999271 http://dx.doi.org/10.1038/s41416-022-01931-2 |
Ejemplares similares
-
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
por: Harrysson, Sara, et al.
Publicado: (2021) -
Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients
por: Harrysson, Sara, et al.
Publicado: (2022) -
Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCLcomplete Project
por: Jerkeman, Mats, et al.
Publicado: (2023) -
Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation
por: Ekberg, Sara, et al.
Publicado: (2022) -
Simplicity at the cost of predictive accuracy in diffuse large B‐cell lymphoma: a critical assessment of the R‐IPI, IPI, and NCCN‐IPI
por: Biccler, Jorne, et al.
Publicado: (2017)